News | February 10, 2023
Lupin Q2 FY23 revenue up 3.9%; Profit down 71%
With the recent sales force expansion and new product launches, we expect to be back to above-market growth
With the recent sales force expansion and new product launches, we expect to be back to above-market growth
LHWRF will work with the State’s Department of Health and Family Welfare for strengthening the healthcare system and addressing the prevalence of CVD and COPD for better outcomes
Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.
Through this agreement, Lupin will introduce two new formulations, a fixed-dose combination of Rifapentine + Isoniazid and Rifapentine 300 mg standalone tablets, at an affordable price
Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.
The inspection of the facility was conducted from August 16-19, 2022.
Lupin is the 6th largest company in the Indian Pharmaceutical Market
The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
Diana is a senior leader with more than 38 years of field experience in U.S. FDA’s Office of Regulatory Affairs (ORA)
Subscribe To Our Newsletter & Stay Updated
